Abstract

To more closely understand the mechanisms of how BCG vaccination confers immunity would help to rationally design improved tuberculosis vaccines that are urgently required. Given the established central role of CD4 T cells in BCG induced immunity, we sought to characterise the generation of memory CD4 T cell responses to BCG vaccination and M. bovis infection in a murine challenge model. We demonstrate that a single systemic BCG vaccination induces distinct systemic and mucosal populations of T effector memory (TEM) cells in vaccinated mice. These CD4+CD44hiCD62LloCD27− T cells concomitantly produce IFN-γ and TNF-α, or IFN-γ, IL-2 and TNF-α and have a higher cytokine median fluorescence intensity MFI or ‘quality of response’ than single cytokine producing cells. These cells are maintained for long periods (>16 months) in BCG protected mice, maintaining a vaccine–specific functionality. Following virulent mycobacterial challenge, these cells underwent significant expansion in the lungs and are, therefore, strongly associated with protection against M. bovis challenge. Our data demonstrate that a persistent mucosal population of TEM cells can be induced by parenteral immunization, a feature only previously associated with mucosal immunization routes; and that these multifunctional TEM cells are strongly associated with protection. We propose that these cells mediate protective immunity, and that vaccines designed to increase the number of relevant antigen-specific TEM in the lung may represent a new generation of TB vaccines.

Highlights

  • Tuberculosis (TB) caused by infection with Mycobacterium tuberculosis or Mycobacterium bovis remains one of the most important infectious diseases of man and animals respectively, and continues to inflict a huge cost in humans and animals in both health and financial terms [1].At present the only available vaccine against TB is M. bovis bacille Calmette-Guerin (BCG) which demonstrates variable efficacy in humans and cattle [2,3]

  • Groups of BALB/c mice were BCG or sham immunized by the intradermal route (i.d.) six weeks prior to i.n. challenge with M. bovis

  • Groups of mice were BCG or sham immunized as described at week 0 or BCG immunized at week 48 and all challenged at week 54

Read more

Summary

Introduction

Tuberculosis (TB) caused by infection with Mycobacterium tuberculosis or Mycobacterium bovis remains one of the most important infectious diseases of man and animals respectively, and continues to inflict a huge cost in humans and animals in both health and financial terms [1].At present the only available vaccine against TB is M. bovis bacille Calmette-Guerin (BCG) which demonstrates variable efficacy in humans and cattle [2,3]. BCG induces effective protection against childhood disseminated TB and tuberculous meningitis, but poor protection against pulmonary TB in adolescents and adults [4]. Despite this inconsistent performance, BCG remains the most widely used human vaccine in the world and due to its partial efficacy and proven safety record, is unlikely to be withdrawn. A deeper understanding of the T cell mechanisms underpinning the immunity induced by BCG vaccination would help to identify immune correlates of protection This would facilitate and accelerate the rational design of improved replacement, or adjunct tuberculosis vaccines

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call